N-(2,4-Pentadienyl)formamid | 62398-16-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-(2,4-Pentadienyl)formamid
• 英文别名: N-penta-2,4-dienylformamide
• CAS: 62398-16-7
• 化学式: C₆H₉NO
• mdl: MFCD19222904
• 分子量: 111.144
• InChiKey: PVZHADPMVQKEIF-UHFFFAOYSA-N

物化性质

• 沸点：
  258.1±19.0 °C(Predicted)
• 密度：
  0.907±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-(2,4-Pentadienyl)formamid 生成 2,4-Pentadienylisocyanid
  参考文献：
  名称：

  Schoellkopf,U. et al., Justus Liebigs Annalen der Chemie, 1977, p. 40 - 50

  摘要：

  DOI：
• 作为产物：
  描述：

  1,3-戊二烯,5-溴- 、 formamide 生成 N-(2,4-Pentadienyl)formamid
  参考文献：
  名称：

  Schoellkopf,U. et al., Justus Liebigs Annalen der Chemie, 1977, p. 40 - 50

  摘要：

  DOI：

文献信息

• Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological atates
  申请人：Clifton Ibert

  公开号：US20070010535A1

  公开（公告）日：2007-01-11

  This invention provides a class of therapeutic compounds and methods for the treatment of mammals with physiological disorders, such as for example a frequently occurring type of essential hypertension, which are critically associated with the decreased binding of magnesium to the plasma membranes of their cells. These methods consist of administering to a mammal in need of such treatment a compound selected from a series of disubstituted trans, trans 1,3-butadienes, 1,3-disubstituted perhydrobutadienes, 1,2-disubstituted trans ethylenes and 1,2 disubstituted ethanes and disubstituted propanes, each of which embodies, in common, the unique structural feature essential for the biological activity of these compounds. This invention also provides for pharmaceutical formulations that employ these novel compounds.
• Antagonist of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
  申请人：Wells Clifton Ibert

  公开号：US20070197659A1

  公开（公告）日：2007-08-23

  This invention provides a class of therapeutic compounds and methods for the treatment of mammals with physiological disorders, such as for example a frequently occurring type of essential hypertension, which are critically associated with the decreased binding of magnesium to the plasma membranes of their cells. These methods consist of administering to a mammal in need of such treatment a compound selected from a series of disubstituted trans, trans 1,3-butadienes, 1,3-disubstituted perhydrobutadienes, 1,2-disubstituted trans ethylenes and 1,2 disubstituted ethanes and disubstituted propanes, each of which embodies, in common, the unique structural feature essential for the biological activity of these compounds. This invention also provides for pharmaceutical formulations that employ these novel compounds.
• US7211667B2
  申请人：——

  公开号：US7211667B2

  公开（公告）日：2007-05-01
• Schoellkopf,U. et al., Justus Liebigs Annalen der Chemie, 1977, p. 40 - 50
  作者：Schoellkopf,U. et al.

  DOI：——

  日期：——